Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
This article breaks down the key drivers behind global stock indices, including economic data, central bank policy, and market sentiment.
20,453 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Rocket Lab reports record backlog and margin gains, while Intuitive Machines pursues a transformative acquisition to ...
This article breaks down surf mobility (SRFM) earnings in plain language. Learn what the SRFM earnings transcript rev...
Quantum computing could reshape industries, and early investors may gain. This guide breaks down three stocks to watc...
OpenAI’s IPO-style risk disclosure confirms Microsoft’s central role in its operations, signaling potential leverage ...
If SpaceX shifts a sizable slice of its IPO to everyday investors, the market could see bigger demand and new pricing...
Starting with $1,000, you can build a durable energy stock portfolio. This guide shows the smartest energy stocks wit...
As markets react to CODI's Q1 2026 results, the codi 2026 earnings call offers a clear view of growth drivers, profit...
A high-stakes clash over FCC rules has echoes for your wallet. This article breaks down how regulatory battles around...
Emcor Group combines breadth in facilities management and electrical/mechanical contracting with a steady financial p...
BTBT's Q4 2025 earnings shed light on mining efficiency, energy spend, and bitcoin price risks. This guide breaks dow...
X-Energy lands ratings from six major firms, with five Buy or Overweight calls and a top target of $57, as investors ...